Viking Therapeutics, Inc.

Viking Therapeutics (VKTX) shows no cyber incidents or red-flag 8-Ks in our 90-day monitoring window, suggesting operational stability in the recent period. However, low signal in a short window does not indicate low overall risk; the company operates in biotech where financing events, share dilution, and clinical trial outcomes drive material risk that extends beyond this snapshot. The full $49 Report pulls 12 months of filing history, quantifies dilution pressure, maps financing trajectories, and flags AI-detected risk signals that may not appear in headline events. The full $49 Report adds dilution risk scoring, comprehensive 8-K context, 12-month financing history, and predictive AI risk signals.